Cantex Pharmaceuticals, Inc. is a clinical stage pharmaceutical company focused on developing novel treatments for cancer and inflammatory lung diseases.
Cantex’s pipeline consists of three product candidates – Azeliragon, Dicopp® and DSTAT. These drugs are in clinical development for cancers for which innovative and more effective treatments are greatly needed.
Azeliragon is an orally administered small molecule, taken once-daily, that inhibits RAGE interactions with its natural ligands, including HMGB1 and S100 proteins produced by cancer cells. Azeliragon was originally under development for Alzheimer’s disease by the company from which we licensed azeliragon. Clinical safety data from these trials, involving over 2000 individuals dosed for periods up to 18 months, indicates that azeliragon is very well tolerated. Cantex is planning clinical trials of azeliragon as a potential treatment for cancer and inflammatory lung diseases.
Dicopp®, which is a proprietary combination of disulfiram + copper, is being developed for the treatment of pediatric sarcoma. A Phase 1/2 study of Dicopp® as a treatment of pediatric saroma is expected to begin in 2022.
DSTAT in collaboration with the US Army Institute of Surgical Research, is being studied pre-clinically for its potential to reduce organ failure and increase survival after severe trauma.